Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Clinical usefulness of serum and plasma vascular endothelial growth factorin cancer patients: Which is the optimal specimen?
Autore:
Lee, JK; Hong, YJ; Han, CJ; Hwang, DY; Hong, SI;
Indirizzi:
Korea Canc Ctr hosp, Dept Clin Pathol, Seoul 139240, South Korea Korea Canc Ctr hosp Seoul South Korea 139240 , Seoul 139240, South Korea Korea Canc Ctr hosp, Dept Internal Med, Seoul 139240, South Korea Korea Canc Ctr hosp Seoul South Korea 139240 , Seoul 139240, South Korea Korea Canc Ctr hosp, Dept Surg, Seoul 139240, South Korea Korea Canc Ctr hosp Seoul South Korea 139240 , Seoul 139240, South Korea
Titolo Testata:
INTERNATIONAL JOURNAL OF ONCOLOGY
fascicolo: 1, volume: 17, anno: 2000,
pagine: 149 - 152
SICI:
1019-6439(200007)17:1<149:CUOSAP>2.0.ZU;2-F
Fonte:
ISI
Lingua:
ENG
Soggetto:
COLORECTAL-CANCER; FACTOR VEGF; BLOOD-PLATELETS; ANGIOGENESIS; CELLS; MEGAKARYOCYTES; EXPRESSION; RELEASE; BIOLOGY;
Keywords:
vascular endothelial growth factor; serum; plasma; cancer cells; platelets;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
28
Recensione:
Indirizzi per estratti:
Indirizzo: Hong, SI Korea Canc Ctr hosp, Dept Clin Pathol, 215-4 Gongneung Dong, Seoul 139240,South Korea Korea Canc Ctr hosp 215-4 Gongneung Dong Seoul South Korea 139240
Citazione:
J.K. Lee et al., "Clinical usefulness of serum and plasma vascular endothelial growth factorin cancer patients: Which is the optimal specimen?", INT J ONCOL, 17(1), 2000, pp. 149-152

Abstract

Vascular endothelial growth factor (VEGF) is secreted by various human cancer cells and plays a key role in cancer angiogenesis and metastasis. Recently, evidence of VEGF storage in blood cells including platelets has been reported. The serum VEGF levels were reported to increase during clotting asa result of its release from platelets, and plasma sample instead of serumwas recommended for measuring the circulating VEGF more accurately. However, platelets have been implicated in tumor metastasis since circulating tumor cells forming aggregates with platelets were observed. The purpose of this study was to clarify which is an optimal specimen to measure VEGF in cancer patients, serum or plasma. We measured serum and plasma VEGF levels andplatelet counts in 173 cancer patients and 42 healthy people, and found that serum VEGF levels were significantly higher than matched plasma VEGF andthe VEGF difference (serum VEGF - plasma VEGF) correlated with platelet counts (r=0.624, p<0.05) in both cancer patients and healthy controls. We selected cancer patients with normal platelet counts (130-400x10(3)/mu l, Pit-normal cancer group). Interestingly, serum VEGF levels were higher in Plt-normal cancer group than in healthy controls. The theoretical platelet-derived VEGF in serum, calculated based on actual blood platelet counts (pg per 10(6) platelets), was also significantly higher in Plt-normal cancer group than in normal controls. It is, therefore, suggested that, although the serum VEGF levels are affected by blood platelets, platelet-derived VEGF also reflect biology of cancer cells, and that serum would be the mole useful specimen for measurement of circulating VEGF in cancer patients for prognosis.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/20 alle ore 03:58:23